Publication | Open Access
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
2.4K
Citations
18
References
2020
Year
In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo. (Funded by Bayer; FIDELIO-DKD ClinicalTrials.gov number, NCT02540993.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1